Michael Secora - May 15, 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief Financial Officer
Signature
/s/Jonathan Golightly, attorney-in-fact
Stock symbol
RXRX
Transactions as of
May 15, 2024
Transactions value $
-$119,740
Form type
4
Date filed
5/17/2024, 07:11 PM
Previous filing
Apr 18, 2024
Next filing
Jun 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Tax liability -$120K -12K -0.97% $10.01 1.22M May 15, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RXRX Stock Option (Right to Buy) 810K May 15, 2024 Class A Common Stock 0 $2.22 Direct F3
holding RXRX Stock Option (Right to Buy) 685K May 15, 2024 Class A Common Stock 0 $2.22 Direct F4
holding RXRX Stock Option (Right to Buy) 3.91K May 15, 2024 Class A Common Stock 0 $11.40 Direct
holding RXRX Stock Option (Right to Buy) 117K May 15, 2024 Class A Common Stock 0 $11.40 Direct F5
holding RXRX Stock Option (Right to Buy) 405K May 15, 2024 Class A Common Stock 0 $8.55 Direct F6
holding RXRX Stock Option (Right to Buy) 348K May 15, 2024 Class A Common Stock 0 $10.09 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F2 This transaction was executed in multiple trades at prices ranging from $7.44 to $7.70 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events.
F4 The option, originally for 1,125,000 shares, vests as to one forty-eighth (1/48th) of the shares subject to the award one month after March 1, 2020, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter.
F5 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F6 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F7 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.